CompletedNCT00523601

Quetiapine for bipolarity depression

About this title

Quetiapine Efficacy in Bipolar Depression Study

Observational studyAges 18–65South Korea

The study in practice

Understand this study

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Kyungki-do and 2 more locationsSee all locations and recruitment

Study clarity

Study start dateJune 2007

Recruitment status: Completed
Enrollment listed in the registry: 2,000
Sponsor: AstraZeneca
Sponsor type: Unknown or unclear
Study type: Observational
Intervention type: Interview / survey / observational
Study phase: Not clearly listed
Locations: South Korea
Age range: From 18 Years to 65 Years
Official registry ID: NCT00523601
Official title: Show the full official title
A 8-Week, Multicenter, Open-Label, Observational Study of the Efficacy of Quetiapine Fumarate (SEROQUEL) Immediate-Release Tablets in Adult Patients With Bipolar Depression

Completed

Kyungki-do · Daejun

FAQ

Who is behind this study?

The study sponsor is AstraZeneca.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.